of therapeutic hypothermia. Multiple investigations were published showing little impact between TTM with the normothermia, prehospital hypothermia, and in-hospital hypothermia strategies on neurologic and mortality outcomes. 5, 6 This led to an alteration in the recommendation for the use of therapeutic hypothermia, with the 2015 American Heart Association guidelines 7 for post-cardiac arrest care instead suggesting that TTM be used rather than strictly outlining a therapeutic hypothermia strategy. The grading of the recommendation was also altered to a class IB level B-R recommendation for out-of-hospital pulseless ventricular tachycardia and ventricular fibrillation cardiac arrest. Furthermore, it was changed to a class IB level C-EO recommendation (consensus of expert opinion based on clinical experience) for out-of-hospital pulseless electrical activity and asystole cardiac arrests and in-hospital cardiac arrests. 7 This was also followed by the recommendation against prehospital intravenous cooled fluid infusion.
Due to the conflicting data, we sought to evaluate the effect that TTM had through normothermia, prehospital hypothermia, and in-hospital hypothermia on in-hospital mortality and neurologic outcomes after cardiac arrest through systematic review and meta-analytic comparisons of the RCTs comparing the 3 TTM strategies.
METHODS
We searched SCOPUS from 1966 until November 2016 for English language RCTs detailing the use of TTM after cardiac arrest in adult patients. The SCOPUS database indexes the full Medline database as well as Biobase, Embase, Fluidex, Geobase, and the World Textile Index. Three authors (P.A., N.S.B., and R.K.) used a prespecified list of terms to locate studies. The full search strategy is detailed in Supplemental Digital Content, Section 1, http://links. lww.com/AA/C138. We also reviewed reference lists from original manuscripts and published systematic reviews and meta-analyses to identify trials that were not listed in the original database search. After review of abstracts, full-text manuscripts were retrieved for review.
All English language RCTs evaluating the use of TTM in adults were eligible for inclusion. All combinations of cardiac rhythms (asystole, pulseless electrical activity, ventricular fibrillation, and pulseless ventricular tachycardia), TTM strategies (prehospital hypothermia, in-hospital hypothermia, and normothermia), and target temperatures were included. Hypothermia was defined as being 34°C or less. Normothermia was defined as being 36°C or more. Foreign language studies were excluded unless a full-text English translation of the study was available.
We intended to compare mortality and neurologic outcomes in patients by categorizing the studies into 2 groups: (1) hypothermia versus normothermia and (2) prehospital hypothermia versus in-hospital hypothermia. The prehospital hypothermia versus in-hospital comparison was done to evaluate whether the timing of hypothermia affected outcomes and to alleviate any concerns about the delay in institution of hypothermia as a cause of null results in the primary comparison (therapeutic hypothermia versus normothermia). These comparisons were decided on in an a priori fashion because the RCTs comparing the 2 approaches have conflicting results. The primary outcome measure was in-hospital all-cause mortality after cardiac arrest. The secondary outcome measure was the cerebral performance category (CPC) after TTM. 8 The CPC scale is a 5-point scale graded from 1 to 5, where the outcome of neurologic disability after significant damage is graded into one of the following 5 categories: good recovery (CPC 1), moderate disability (CPC 2), severe disability (CPC 3), persistent vegetative state (CPC 4), or death (CPC 5). 8 Within this scale, good neurologic outcome was defined as CPC categories 1-2 and poor neurologic outcomes were defined as CPC categories 3-5 for meta-analyses. Discharge to rehabilitation facilities was classed as CPC 2 and discharge to a nursing home was classified as CPC 3. A CPC score of 2 or less was considered a favorable neurologic outcome. 2 Where there were multiple studies reporting outcomes for the same cohort, we chose the study with the longest and most complete follow-up.
Four authors (P.A., N.S.B., R.K., and G.A.) searched the titles and abstracts of all studies. Multiple authors (G.A., N.S.B., and R.K.) then performed data extraction. Data were extracted to elucidate baseline characteristics of patients and outcome measures in all of the included studies. All inconsistencies during data extraction were resolved by mutual consensus so that a unanimous decision was made.
Quality assessment of the included studies was performed according to the Jadad scale for RCTs. 9 The Jadad scale evaluates the quality of RCTs through assessment of study randomization, blinding, and description of withdrawals and dropouts. Two authors (N.S.B. and R.K.) independently performed quality assessment of all of the included RCTs using the Jadad scale. 9 The systematic review and meta-analyses were reported based on the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 10 
Statistical Analysis
Statistical analyses were performed by Comprehensive Meta-Analysis version 2.2.046 (Biostat, Englewood, NJ) and STATA version 14.1 (StataCorp LP, College Station, TX). To estimate summary effects, a random effects model using the DerSimonian and Laird 11 method was used in our investigation. The Mantel-Haenszel model was then used to estimate the heterogeneity for the meta-analyses. 12 Heterogeneity was estimated using the I 2 statistic proposed by Higgins and Thompson. 12 Summary treatment effects and results were presented as risk ratios (RR) with 95% confidence intervals (CIs). Funnel plots were generated to outline the publication bias. We used log RR as the x-axis variable to exhibit estimated treatment effect for the included studies and plotted standard error as the y-axis variable to provide a measure of sample size. 13 Publication bias was assessed using the Egger regression intercept.
14 The Egger regression test is a simple linear regression to detect asymmetry of the funnel plot on the logarithm scale of the risk ratio.
14 The 1-sided Egger test was used because the 2-sided test may produce a false publication bias or inconsistency in the tail. 15, 16 Based on the estimated standard normal deviate (treatment effect size divided by standard error) and the precision (the inverse of standard error) of the included studies, an Egger regression line is generated. If there is symmetry in the funnel plot, the intercept should be nonsignificant. In other words, the intercept value should be zero or near zero, and deviation of intercept from zero suggests publication bias. However, the power of the Egger regression test proportionally increases with number of studies. 14, 16 A limited number of studies may have low power to detect publication bias. In case of significant heterogeneity in primary outcome among either comparison, meta-regression analyses were conducted in post hoc fashion using a mixed-effects (unrestricted maximal likelihood) meta-regression model to explore the reasons for the heterogeneity. The variables used for meta-regression were age, bystander cardiopulmonary resuscitation (CPR), presenting rhythm, and duration of return to spontaneous circulation (ROSC) on treatment effects comparisons between hypothermia and normothermia trials. Power calculations were performed assuming a 20% reduction in mortality and adverse neurologic outcome as a clinically important treatment effect for the hypothermia versus normothermia comparison. 5 Conversely, for the prehospital hypothermia versus in-hospital hypothermia comparison, a 15% reduction mortality and adverse neurologic outcome was considered clinically important. 17 These calculations were based on the assumptions that the number of patients and the outcome rate in the control group are equal to those in our meta-analysis. A 2-sample proportions the Pearson χ 2 test was used to compute power.
RESULTS
Eleven RCTs ( Figure 1 ) with 4782 patients were eligible for analyses (Table 1) . 2, 3, 5, [18] [19] [20] [21] [22] [23] [24] [25] The results of this systematic review and meta-analyses are presented as per the PRISMA extension statement (Supplemental Digital Content, Table 1 , http:// links.lww.com/AA/C138). 10 All included studies were graded as good to excellent based on the Jadad scale (Supplemental Digital Content, Table 2 , http://links.lww.com/AA/C138).
There was variation in the individual characteristics of the trials. The mean/median age of the patients in the prehospital hypothermia, in-hospital hypothermia, and normothermia arms ranged from 63 to 67, 61 to 67, and 59 to 69 years of age, respectively. Mean/median ROSC time in the prehospital hypothermia, in-hospital hypothermia, and normothermia arms ranged from 26 to 32, 21 to 30, and 22 to 28 minutes, respectively. All combinations of presenting rhythms during out-of-hospital cardiac arrest were studied. There was a predominance of male patients in nearly all study arms (Table 1) .
There were also variations in the resuscitation and cooling protocols of the trials. Percentage of bystander CPR varied from 26% to 73% among all study arms. The prehospital and in-hospital hypothermia arms of the trials had target temperatures ranging from 32 to 34°C. The duration of cooling in the prehospital hypothermia and in-hospital hypothermia arms ranged from 12 to 28 hours. Multiple methods of cooling were used, such as cooling via a helmet, ice packs, and intravenous infusion of cooled fluids (Table 1) . These interventions were studied in 2 groups: (1) the hypothermia versus normothermia comparison (studies = 5 and patients = 1389) 2,3,5,18,23 and (2) the prehospital hypothermia versus in-hospital hypothermia comparison (studies = 6, patients = 3393). [19] [20] [21] [22] 24, 25 Hypothermia Versus Normothermia Among the 5 RCTs that compared the hypothermia and normothermia strategies, 2,3,5,18,23 702 patients received hypothermia as part of postarrest care, whereas 687 received normothermia. We observed no difference in all-cause mortality rates in the hypothermia versus normothermia comparison (RR, 0.88; 95% CI, 0.73-1.05; Figure 2A ). Similarly, we did not observe any difference in the rates of favorable neurologic outcome in the hypothermia versus normothermia comparison (RR, 1.26; 95% CI, 0.92-1.72; Figure 2B ).
Prehospital Hypothermia Versus In-Hospital Hypothermia
Among the 6 RCTs that compared the prehospital hypothermia and in-hospital hypothermia strategies, [19] [20] [21] [22] 24, 25 1722 patients received prehospital hypothermia as part of postarrest care, whereas 1671 received in-hospital hypothermia. We observed no difference in all-cause mortality rates in the prehospital hypothermia versus in-hospital hypothermia comparison (RR, 1.00; 95% CI, 0.97-1.03; Figure 3A ). Similarly we did not observe any difference in the rates of favorable neurologic outcome in the prehospital hypothermia versus in-hospital hypothermia comparison (RR, 0.96; 95% CI, 0.85-1.08; Figure 3B ).
Meta-regression to Explore Heterogeneity in All-Cause Mortality Across Trials
We observed a substantial heterogeneity in treatment effect for mortality across trials comparing hypothermia and normothermia (I 2 = 44%; Figure 2A ) No heterogeneity was seen in trials comparing prehospital hypothermia and in-hospital hypothermia (I 2 = 0%; Figure 3A ). We conducted a post hoc analysis to see if age, bystander CPR, presenting rhythm, and time to ROSC would explain this heterogeneity. In studies comparing normothermia and hypothermia, we observed a significant trend toward a favorable effect of hypothermia on all-cause mortality with decreasing proportion of patients undergoing bystander CPR (P = .04). The other characteristics were not related to treatment effect of mortality (P > .05; Table 2 ).
Publication Bias
Publication bias was assessed using the Egger regression intercept for the primary outcome for the normothermia versus hypothermia and prehospital hypothermia versus in-hospital hypothermia comparisons. We did not observe any significant publication bias ( Figure 4A, B) . Figure 2 . A, Forest plot comparing all-cause mortality between hypothermia and normothermia. B, Forest plot comparing favorable neurologic outcome between hypothermia and normothermia. The blue diamond depicts the point estimate and the 95% confidence interval. The red dotted lines represent a random effects generated overall estimate. This was generated with a random effects model using the method of DerSimonian and Laird, 11 with the estimate of heterogeneity calculated from the Mantel-Haenszel model. Data are presented with risk ratios and 95% confidence intervals. CI indicates confidence interval; HT, hypothermia; NT, normothermia; RR, risk ratio.
Power Calculation
We observed that >90% power would be achieved for mortality comparisons for both the hypothermia versus normothermia and prehospital hypothermia versus in-hospital hypothermia comparisons under this premise. For favorable neurologic outcome, the hypothermia versus normothermia comparison would achieve a power of >80%, whereas the prehospital hypothermia versus in-hospital hypothermia comparison would achieve a power of 62%. The prehospital hypothermia versus in-hospital hypothermia comparison Figure 3 . A, Forest plot comparing all-cause mortality between prehospital hypothermia and in-hospital hypothermia. B, Forest plot comparing favorable neurologic outcome between prehospital hypothermia and in-hospital hypothermia. The blue diamond depicts the point estimate and the 95% confidence interval. The red dotted lines represent a random effects generated overall estimate. This was generated with a random effects model using the method of DerSimonian and Laird, 11 with the estimate of heterogeneity calculated from the Mantel-Haenszel model. Data are presented with risk ratios and 95% confidence intervals. CI indicates confidence interval; IH, in-hospital hypothermia; PH, prehospital hypothermia; RR, risk ratio. The interpretation is valid in between the specified range of variables. β estimate >0 indicates risk ratio >1. Meta-regression analyses were conducted using a mixed-effects meta-regression (unrestricted maximal likelihood) model. Abbreviations: CI, confidence interval; CPR, cardiopulmonary resuscitation; ROSC, return to spontaneous circulation.
may be affected by a future trial as the power to detect a clinically important treatment effect in neurologic outcome was low (Supplemental Digital Content, Table 3 , http:// links.lww.com/AA/C138).
DISCUSSION
Our systematic review and meta-analyses explore and compare the mortality and neurologic outcomes in cardiac arrest patients undergoing in-hospital hypothermia, prehospital hypothermia, and the normothermia TTM strategies. Despite heterogeneity in the duration of cooling, target temperatures, and presenting rhythms, we found that there was no difference in mortality or neurologic outcomes when comparing these strategies. There are likely several mechanistic explanations for our findings. Therapeutic hypothermia and TTM as a whole have been under investigation for well over a decade. Along with the release of a number of high-profile RCTs, consensus guidelines have moved toward protocol-driven post-cardiac arrest care. The emergence of therapeutic hypothermia strategies may have led to the institution of formal protocols for post-cardiac arrest care where they were previously lacking. There are some data to suggest improvement in mortality after implementation of such protocols and this is similar to trends seen elsewhere in medicine, such as in the treatment of sepsis. Hence, we postulate that making post-cardiac arrest care more standardized may well have itself improved the outcomes of post-cardiac arrest patients, thereby neutralizing some of the effects conferred by therapeutic hypothermia strategies. Additionally, the physiologic effect of cooling on cardiac function remains unclear. There are conflicting data on the topic, with some reports to suggest that in transplant patients there is less damage to the donor heart in the absence of profound hypothermia and therefore improvement in cardiac function. 26 Conversely, Shao et al 27 reported benefit after starting a therapeutic hypothermia at lower temperatures in an animal model by potentially reducing cardiac myocyte death through generation of nitric oxide. However, this appears to itself conflict with clinical data by Bernard et al 22 in the form of the recently published Rapid Infusion of Cold Normal Saline (RINSE) trial. These conflicting data raise important questions about the physiologic implications of hypothermia on cardiac function and the timing of institution of hypothermia. We hoped to address the latter question through our investigation. More importantly, it suggests that the mechanisms are largely unclear to us and that manipulating this delicate physiology may induce harm. This is particularly important when a significant proportion of deaths after use of therapeutic hypothermia are due to a cardiac cause. Finally, we note that there is a vast difference in the percentage of patients receiving bystander CPR before initiation of therapeutic hypothermia in the trials. This ranged from 26% to 73% in the included trials. 5, 18 Because early and good-quality CPR is very clearly linked to survival after cardiopulmonary arrest, 28, 29 we postulate that the large variation in percentage of patients receiving CPR may have been a confounding factor in the mortality and neurologic outcome results attributed to therapeutic hypothermia protocols.
Our findings can also be used to draw interesting conclusions when compared to the existing literature base. There appears to be a significant interest in TTM and this has led to the publication of numerous meta-analyses and a Cochrane review that attempt to summarize the literature. To the best of our knowledge, our investigation remains the first to use meta-analyses to compare mortality and neurologic outcomes between the prehospital hypothermia, inhospital hypothermia, and normothermia strategies. Most of the other investigations are limited by sole comparisons between the prehospital hypothermia and normothermia strategies. [30] [31] [32] [33] [34] Of these published meta-analyses, 1 investigation included only nonshockable rhythms 35 and another primarily included the results of cohort studies. 31 We also note the trend in the meta-analyses published after 2014 to largely suggest that therapeutic hypothermia does not confer a benefit with regards to neurologic outcome or mortality. This may be affected by the inclusion of the investigation authored by Nielsen et al, 5 which was the largest trial to suggest this. We www.anesthesia-analgesia.org
note that similar results were reflected in the recently published RINSE trial authored by Bernard et al. 22 There are also important clinical implications of our findings. Induction of therapeutic hypothermia and care of therapeutic hypothermia is associated with a significant cost to modern health care system. This has been estimated to be somewhere between $100,000 and $160,000 per hospitalization per patient treated. 36 In the modern era, this economic concern cannot be discarded if the proven outcome remains unclear. Therapeutic hypothermia is also associated with significant risks during the rewarming period. If patients are able to achieve equally good neurologic and mortality outcomes without the use of the hypothermia strategy, then clinicians may well be able to ameliorate some of these risks through avoidance of therapeutic hypothermia. We also note that there are further trials aiming to examine the future of therapeutic hypothermia. 37 The Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm (HYPERION) trial 37 is a multicenter randomized controlled superiority trial that aims to compare neurologic status and mortality outcomes in patients with cardiac arrest due to a nonshockable rhythm. This trial aims to compare patients treated with a TTM strategy maintaining a temperature between 32.5°C and 33.5°C to patients treated with a TTM strategy maintaining a temperature between 36.5°C and 37.5°C. 37 We hope that this will yield information as to whether it is therapeutic hypothermia or simply a TTM normothermic strategy with avoidance of fever that confers neurologic or mortality benefit.
Kämäräinen et al 23 note differences in the rates of bystander CPR in the 2 groups and minor differences in the end-tidal carbon dioxide measurements at the time of hospital admission. Hence we evaluated the effect of rates of bystander CPR on treatment effect using meta-regression. Both our meta-analysis and recent evidence suggests that conventional bystander CPR confers a clear mortality benefit over both no compression CPR and no bystander CPR. 38 Such evidence highlights the need to create prediction models to identify who may benefit from hypothermia, such as patients who have not received bystander CPR. Hypothermia has been demonstrated in animal models to reduce ischemia-reperfusion injury, suppress ischemiainduced inflammatory cytokine surge, reduce free radicals, protect blood-brain barrier integrity and resultant brain edema/intracranial hypertension, improve brain glucose metabolism, reduce convulsive activity, and increased expression of immediate early genes which may prevent stress injury. [39] [40] [41] [42] [43] The important distinction between animal and human studies is that the former are conducted in a tightly controlled environment with rapid and effective institution of mild hypothermia. On the other hand, human studies often have heterogeneity in the aforementioned. There are also key differences in the "bundle of care" in postarrest settings across human studies. This may also reduce the efficacy of hypothermia in humans. Hence future studies should aim to differentiate the effectiveness of hypothermia from other standard of care treatments that are instituted in postarrest settings to identify individuals who may benefit the most from hypothermia.
We recognize that our analyses also have limitations. Amalgamation of data in the form of meta-analyses has well-recognized limitations. 13 Furthermore, we acknowledge significant differences in the cooling methods, cooling protocols, and even the rewarming protocols of the included trials (Table 1) . This remains a topic of great discussion and we hope that future studies will help to derive the optimal protocols for these characteristics. Moreover, in the contemporary trials, therapeutic hypothermia was compared to the standard of care. This was poorly defined given that most of these trials were multicenter trials, some of which took place over multiple countries. We acknowledge that the standard of care likely became more protocol-driven, and therefore more homogeneous, as the trials integrated newer consensus guidelines due to the development of an evidence base for postresuscitation care. However, we feel that this may be a more accurate depiction of modern-day care and this consistency in care provision should be heralded as an important advance in the care of post-cardiac arrest patients.
In conclusion, TTM after cardiac arrest is an integral part of postresuscitation care. Our analyses showed that the normothermic TTM strategy and the prehospital and inhospital hypothermia TTM strategies produced comparable mortality and neurologic outcomes. More RCTs are required to determine the ideal timing, protocol, and patient population that would benefit from these interventions. E
